Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Tuma
Rabiya S
RS
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic / Q000379:methods; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D018579:Patient Selection; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D000068878:Trastuzumab